Septerna Inc.

NASDAQ: SEPN · Real-Time Price · USD
7.66
0.52 (7.28%)
At close: May 02, 2025, 12:46 PM
7.28%
Bid 5.4
Market Cap 340.77M
Revenue (ttm) 539K
Net Income (ttm) -17.24M
EPS (ttm) -7.26
PE Ratio (ttm) -1.05
Forward PE -2.38
Analyst Buy
Ask 9.2
Volume 52,144
Avg. Volume (20D) 516,433
Open 7.21
Previous Close 7.14
Day's Range 7.16 - 7.67
52-Week Range 4.17 - 28.99
Beta 4.26

About SEPN

Septerna, Inc., a clinical-stage biotechnology company, discovers and develops G protein-coupled receptor (GPCR) oral small molecule products candidates for the treatment of endocrinology, immunology and inflammation, and metabolic diseases. The company develops SEP-786, an oral small molecule PTH1R agonist for hypoparathyroidism; SEP-631, an oral small molecule MRGPRX2 NAM for chronic spontaneous urticaria and other mast cell diseases; TSHR Prog...

Industry Biotechnology
Sector Healthcare
IPO Date Oct 25, 2024
Employees 75
Stock Exchange NASDAQ
Ticker Symbol SEPN
Full Company Profile

Analyst Forecast

According to 4 analyst ratings, the average rating for SEPN stock is "Buy." The 12-month stock price forecast is $38, which is an increase of 396.41% from the latest price.

Stock Forecasts
2 months ago
-46.99%
Septerna shares are trading lower after the compan... Unlock content with Pro Subscription